There was indeed a difference in the HER2 status of breast cancer before and after neoadjuvant therapy, and the difference was statistically significant (P=0.014), and the HER2 status was inconsistent (Kappa=0.630, P<0.001). The gene discussed is ERBB2; the disease is breast carcinoma.